Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Increase in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 246,970 shares, a growth of 252.3% from the May 14th total of 70,108 shares. Based on an average daily volume of 112,419 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of Lixte Biotechnology in the fourth quarter worth about $57,000. Federation des caisses Desjardins du Quebec lifted its holdings in shares of Lixte Biotechnology by 83.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after acquiring an additional 42,530 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Lixte Biotechnology by 47.0% in the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after acquiring an additional 34,350 shares during the last quarter. DRW Securities LLC lifted its holdings in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after acquiring an additional 5,645 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Lixte Biotechnology by 25.9% in the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares during the last quarter. Institutional investors own 5.10% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lixte Biotechnology presently has a consensus rating of “Sell”.

Lixte Biotechnology Stock Up 5.2%

Shares of LIXT stock traded up $0.36 on Thursday, reaching $7.25. The company had a trading volume of 442,109 shares, compared to its average volume of 193,486. The stock has a market capitalization of $108.90 million, a PE ratio of -6.42 and a beta of 1.27. Lixte Biotechnology has a one year low of $0.64 and a one year high of $7.51. The business’s 50-day moving average is $4.74 and its 200 day moving average is $3.91.

Lixte Biotechnology (NASDAQ:LIXT) last posted its earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.